Compare · DNAY vs ELV
DNAY vs ELV
Side-by-side comparison of Codex DNA Inc. (DNAY) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNAY and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 424.4x DNAY ($213.9M).
- ELV has hit the wire 3 times in the past 4 weeks while DNAY has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 5 for DNAY).
- Company
- Codex DNA Inc.
- Elevance Health Inc.
- Price
- $1.20-4.76%
- $418.31+0.63%
- Market cap
- $213.9M
- $90.81B
- 1M return
- -
- +12.19%
- 1Y return
- -
- +7.35%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 5
- 23
Codex DNA Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest DNAY
- SEC Form 4 filed by Kullback William J
- SEC Form 3 filed by new insider Kullback William J
- Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Codex DNA Inc.
- Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Codex DNA Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- Herrema Gregory J. was granted 153,191 shares (SEC Form 4)
- SEC Form 3 filed by new insider Herrema Gregory J.
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)